Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by significant unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, Entrada aims to tackle RNA and protein dysfunctions associated with muscular dystrophies and genetic disorders. The company has developed a robust clinical pipeline underscored by a commitment to scientific excellence and is led by a seasoned management team with extensive industry expertise. With its strategic focus and cutting-edge therapeutic solutions, Entrada is well-positioned to drive meaningful advancements in patient care and establish itself as a leader in the biopharmaceutical sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$6.42
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 5, 2026 | $-1.16 | $-1.01 | Beat +12.9% | $-1.01 | $2.23M | $898K | -59.7% | 1D Pre-0.3% | On-Day-2.5% | 1D Post-2.7% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-1.02 | $-0.95 | Beat +6.9% | $-0.95 | $2.92M | $875K | -70.0% | 1D Pre+1.8% | On-Day-57.3% | 1D Post-0.1% |
Q ended Dec 31, 2025 Reported Feb 26, 2026 | $-1.32 | $-0.94 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $7.41M |
| $1.3M |
| -82.5% |
| 1D Pre+4.4% |
| On-Day+6.8% |
| 1D Post-6.7% |
Q ended Sep 30, 2025 Reported Nov 6, 2025 | $-0.96 | $-1.06 | Miss -10.4% | — | $8.62M | $1.61M | -81.3% | 1D Pre+4.8% | On-Day+0.1% | 1D Post-0.6% |